Back to News
Market Impact: 0.2
Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Propanc Biopharma announced preclinical data for a pancreatic pro-enzyme (PRP) formulation being studied for pancreatic and ovarian cancer. The report provides no numerical results or further details on efficacy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PPCB0.45
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Nscale, Anthropic Eye $45 Billion Cloud Deal as AI Trade Rebounds
- Elice shares plunge 28% on debut as investor doubts over AI trade deepen
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Alibaba Backs Chinese Robovan Maker in $400 Million Fundraising
- X-Energy CEO on Amazon, AEP Nuclear Data Center Deal